75F40121C00138

STIMULATE INNOVATION IN CLINICAL EVALUATIONS AND PERSONALIZED MEDICINE TO IMPROVE PRODUCT DEVELOPMENT AND PATIENT OUTCOMES.

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	FDA OFFICE OF ACQ GRANT SVCS
NAICS	541990 — All Other Professional, Scientific, and Technical Services
PSC	AN41 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	FIRM FIXED PRICE
Obligations	$1.0M
Current contract value	$1.0M
Potential contract value / ceiling	$1.0M
Start date	Sep 23, 2021
Current end date	Sep 29, 2024
Potential end date	Sep 29, 2024
Latest award activity	Mar 26, 2026
Source loaded	Sep 19, 2026

Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Mar 26, 2026	P00004	$-7.9K	THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE FUNDS AND CLOSE OUT THE CONTRACT.

Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.

Contact	Role	Published contact methods	Evidence	Source date
Kimberly DeLong	Contact	kimberly.delong@fda.hhs.gov 2404028639	Source	May 26, 2021
Robert Maydwell	Contact	Robert.Maydwell@fda.hhs.gov 301-348-1814	Source	May 26, 2021
Kimberly DeLong	Contact	kimberly.delong@fda.hhs.gov 2404028639	Source	May 26, 2021
Anthony S. Wimbush	Contact	anthony.wimbush@fda.hhs.gov 2404027628	Source	May 26, 2021
Kimberly DeLong	Contact	kimberly.delong@fda.hhs.gov 2404028639	Source	Jan 28, 2021
Anthony S. Wimbush	Contact	anthony.wimbush@fda.hhs.gov 2404027628	Source	Jan 28, 2021
Benjamin Golway	Contact	Benjamin.Golway@fda.hhs.gov 3018374464	Source	Nov 20, 2020
Anthony S. Wimbush	Contact	anthony.wimbush@fda.hhs.gov 2404027628	Source	Nov 20, 2020